lifestyle.projectdiaspora.org

Author: CervoMed Inc.

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology

April 30, 2026
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

April 30, 2026
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

April 29, 2026
CervoMed to Participate in Upcoming Investor Conferences

April 28, 2026
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

April 28, 2026
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

February 18, 2026